| abstract |
Sulfamide-derived compounds, having formula (I) wherein R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclic, heterocycloalkyl, heteroalkyl, or- (alkylene) -C (O) -X, or R1 and R2 together with the carbon atom to which they are attached form a carbocycle or a heterocycle; R3 is hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, aryl, aralkyl, ara lkenyl, heteroaryl, heteroaralkyl, heteroalkenyl, heterocycloalkyl, heteroalkyl, (diphenylmethyl) -alkyl, or - (alkylene) -C (O) -X; or R3 together with R1 or R2 and the atoms to which they are attached form a heterocycloamino group: R10 is -NR11OR12; R20 and R21 are independently selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaralkyl, or heteroaralkenyl; or R20 and R21 together with the nitrogen atom to which they are attached form a heterocycloamino group or an optionally substituted tetrahydropyridine or hexahydroazepine ring; or either of R20 or R21 together with R3 forms an alkylene group; and their pharmaceutically acceptable salts, prodrugs, individual isomers, and mixtures of isomers, with the condition of R20 and R21 together with the nitrogen atom to which they are attached do not form a morpholino ring: (i) when R1 and R3 are hydrogen and R2 is aralkyl; or (ii) when R1 and R3 together with the atoms to which they are attached form a tetrahydroisoquinoline ring and R2 is hydrogen; and compounds of formula (I) wherein R1, R2 and R3 are as defined above and R10 is -OH; R20 is hydrogen or alkyl, and R21 is cycloalkyl, aryl, aralkyl, aralkenyl, heteroaryl, or heteroaralkenyl; or R20 and R21 together with |